Calidi Biotherapeutics (CLDI) vs Ernexa Therapeutics (ERNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ernexa Therapeutics is the larger company by market cap ($4.1 million vs $3.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | ERNA |
|---|---|---|
| Share price | $1.04 | $2.49 |
| Market cap | $3.82M | $4.06M |
| 1-day change | +2.97% | +4.18% |
| EPS (TTM) | $-36.47 | $-13.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $71.50 |
| 52-week low | $0.986 | $2.14 |
| Distance from 52-week high | -96.26% | -96.52% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1104.82% |
| Average volume | 255.53K | 472.81K |
| Shares outstanding | 3.68M | 1.63M |
| Employees | 29 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Healthcare · Biotechnology · 29 employees
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Healthcare · Biotechnology · 5 employees
CLDI vs ERNA FAQ
Which is bigger, Calidi Biotherapeutics or Ernexa Therapeutics?
Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $4.06M compared with $3.82M for Calidi Biotherapeutics (CLDI).
Are Calidi Biotherapeutics and Ernexa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.